Delhi-based Dabur Pharma Limited and its subsidiary Dabur Oncology Plc are new to join Eloxatin patent infringement dispute following Sanofi’s complaint in the US District Court for the District of New Jersey alleging infringement of US Patent Nos. 5,338,874 (the ‘874 patent) and 5,716,988 (the ‘988 patent). In separate complaint, Sanofi also extended allegation of patent infringement against Teva Pharmaceutical Industries over the same patents. The complaint is result of Dabur submission of Abbreviated New Drug Application (ANDA) No. 78-811 with the US FDA for the generic approval of Oxaliplatin solution before the expiration of Orange Book listed patents. Earlier, Sanofi filed a patent infringement complaint against Sandoz over the same US patents.
I found some interesting information about ELOXATIN. Check it out!
ReplyDelete